Steward Partners Investment Advisory’s AIM ImmunoTech AIM Stock Holding History

Steward Partners Investment Advisory’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$1	–	4901
2026 Q1	$1	Hold	2	–	–	﹤0.01%	4416
2025 Q4	$2	Hold	2	–	–	﹤0.01%	4304
2025 Q3	$5	Hold	2	–	–	﹤0.01%	4251
2025 Q2	$17	Hold	2	–	–	﹤0.01%	4094
2025 Q1	$27	Buy	+2	New	+$32	﹤0.01%	3983
2021 Q2	–	Sell	-50	Closed	-$11.3K	–	7626
2021 Q1	$11.3K	Buy	+50	New	+$11.3K	﹤0.01%	2731

Other funds holding AIM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSC

Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Steward Partners Investment Advisory's AIM Position: Q2 2026 in Review

Steward Partners Investment Advisory sold out of AIM ImmunoTech (AIM) in Q2 2026, closing a stake of 2 shares — an estimated $1 sold.

Steward Partners Investment Advisory first reported a position in AIM in Q1 2021 and held it in 6 quarters. The position peaked at $11.3K in Q1 2021. 18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.

Steward Partners Investment Advisory reported no remaining AIM ImmunoTech position as of Q2 2026 after selling out during the quarter.
Steward Partners Investment Advisory sold 2 AIM ImmunoTech shares in Q2 2026, an estimated $1.
Steward Partners Investment Advisory first reported a position in AIM ImmunoTech in Q1 2021 and held it in 6 quarters.
Steward Partners Investment Advisory's AIM ImmunoTech position peaked at $11.3K in Q1 2021.
18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.